Gynecological Oncology Group and Advanced Ovarian Cancer
Links shared publicly online about this topic
Oncology Article | Ovarian Neoplasms
mdlinx.com — “Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers” View full resource at mdlinx.com
Most Recently Shared on January 28, 2011 at 1:02 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers: Gynecologic Oncology http://bit.ly/flPBMY #oncology
Ovarian Cancer: eMedicine Oncology
emedicine.medscape.com — “Overview: Ovarian cancer is the most common cause of cancer death from gynecologic tumors in the United States. Early disease causes minimal, nonspecific, or no symptoms. Therefore, most cases are diagnosed in an advanced stage. Overall, prognosis ...” View full resource at emedicine.medscape.com
Most Recently Shared on April 12, 2010 at 6:04 pm By:
Medscape Oncology Oncology and Health Site
Ovarian Cancer: Study finds cytoreductive surgery safe and effective in platinum-sensitive recurrent ovarian cancer. http://bit.ly/9ZmUBA
Oncology Article | Ovarian Neoplasms
mdlinx.com — “Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: A retrospective study of the North-Eastern German Society of Gynecologic Oncology (NOGGO) Ovarian Cancer Study Group” View full resource at mdlinx.com
Most Recently Shared on July 25, 2011 at 10:13 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: A retrospective study of the... http://bit.ly/nkQPud #oncology
Does Bevacizumab Improve Outcomes in Advanced Ovarian Cancer? Video
vodpod.com — “Maurie Markman, M.D. (M.D. Anderson Cancer Ctr.) discusses important gynecologic abstracts to be presented at the 2010 Annual ASCO Mtg. to be held June 4-8, 2010. 04 June 10. : Dr. Maurie Markman previews the findings of the latest Gynecologic Oncology Group study as well as a provocative but preliminary study on the value of screening for ovarian cancer.” View full resource at vodpod.com
Most Recently Shared on June 4, 2010 at 4:47 pm By:
Paul Cacciatore Patient Advocate
Maurie Markman, M.D. (M.D. Anderson Cancer Ctr.) discusses important gynecologic abstracts to be presented at the 2010… http://bit.ly/a2FqDg
EGEN, Inc. Announces That Phase II Clinical Trial For Advanced Ovarian Cancer Is Open For Enrollment
medicalnewstoday.com — “EGEN, Inc. announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment. The trial is sponsored by the Gynecologic” View full resource at medicalnewstoday.com
Most Recently Shared on December 15, 2010 at 6:05 pm By:
MNT Ovarian Cancer Health News
EGEN, Inc. Announces That Phase II Clinical Trial For Advanced Ovarian Cancer Is Open For Enrollment http://mnt.to/3P6r #ovariancancer
ScienceDirect - Gynecologic Oncology : A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group
sciencedirect.com — “ScienceDirect - Gynecologic Oncology : A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study” View full resource at sciencedirect.com
Most Recently Shared on May 31, 2011 at 4:15 am By:
Paul Cacciatore Patient Advocate
GOG ph. 2 study: M.D. Anderson finds wkly nab-paclitaxel has clinical efficacy in resistant/refractory ovarian cancer. http://dld.bz/abFcJ
Oncology Article | Topotecan Ovarian Neoplasms
mdlinx.com — “Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: A randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group” View full resource at mdlinx.com
Most Recently Shared on December 7, 2010 at 6:40 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer... http://bit.ly/fVA9K7 #oncology
Oncology Article | Carcinoma Ovarian Neoplasms Peritoneal Neoplasms
mdlinx.com — “Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial” View full resource at mdlinx.com
Most Recently Shared on November 24, 2010 at 6:57 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic... http://bit.ly/hmPEF6 #oncology
Overcoming ovarian cancer
physorg.com — “(PhysOrg.com) -- UCI's gynecologic oncology group forges what is being called the largest breakthrough for treating ovarian cancer in more than a decade.” View full resource at physorg.com
Most Recently Shared on July 6, 2010 at 8:04 pm By:
PhysOrg Health News Health News
Overcoming ovarian cancer http://tw.physorg.com/197651043
ScienceDirect - Gynecologic Oncology : Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma
sciencedirect.com — “ScienceDirect - Gynecologic Oncology : Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma” View full resource at sciencedirect.com
Most Recently Shared on May 31, 2011 at 4:00 am By:
Paul Cacciatore Patient Advocate
Canadian researchers find most pts w/adv or recur ovarian clear cell cancer receive little benefit frm palliative chemo. http://dld.bz/abFbZ
Oncology Article | Ovarian Neoplasms
mdlinx.com — “Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer” View full resource at mdlinx.com
Most Recently Shared on December 9, 2010 at 10:51 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevaciz... http://bit.ly/frDP6z #oncology
Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer
news-medical.net — “Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.” View full resource at news-medical.net
Most Recently Shared on June 7, 2010 at 12:55 pm By:
Ovarian Cancer News: Genentech reports results from Phase III study of Avastin in women with advanced ovarian ca... http://buzzup.com/zltn
Florida Gynecologic Oncology Center, Treatment, Research, & Support | Florida Hospital Gynecologic Oncology Center
floridahospitalgyncancer.com — “Florida Hospital Gynecologic Oncology Center is a first class Florida Gynecologic Cancer Institute specializing in Gynecologic oncology treatment, clinical trials, oncology research, and Gynecologic cancer support groups and additional services for Gynecologic cancer patients and their families.” View full resource at floridahospitalgyncancer.com
Most Recently Shared on September 15, 2011 at 2:28 pm By:
Don't forget to schedule your annual screenings and tell loved ones to as well! #OvarianCancerAwarenessMonth http://t.co/PxVWLEEO
Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward
newswise.com — “Calgary-based Oncolytics Biotech Inc. recently announced that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.” View full resource at newswise.com
Most Recently Shared on September 14, 2010 at 4:30 pm By:
newswise Health Communicator and Health News
Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward: http://bit.ly/aytD49
Oncolytics initiates enrollment in Phase II ovarian cancer study
news-medical.net — “Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).” View full resource at news-medical.net
Most Recently Shared on December 2, 2010 at 8:52 am By:
Oncolytics initiates enrollment in Phase II ovarian cancer study: Oncolytics Biotech Inc. announced today the st... http://bit.ly/gif7vu
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Medscape Oncology
Medical news, full text journal articles, clinical reference, expert commentary & community features vital for todays oncologist
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
